Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924943 | 0.87 | SLC6A4 (0.67) | TACR1SLC6A4OPRD1SLC6A2SLC6A3 | |
| SCHEMBL924001 | 0.82 | MC4R (0.49) | TACR1SLC6A4OPRD1SLC6A2SLC6A3 | |
| SCHEMBL926471 | 0.80 | SLC6A4 (0.51) | TACR1SLC6A4OPRD1SLC6A2SLC6A3 | |
| SCHEMBL924699 | 0.80 | OPRM1 (0.69) | OPRD1SLC6A3KCNH2OPRM1SIGMAR1 | |
| SCHEMBL8569135 | 0.79 | SLC6A4 (0.72) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL13543093 | 0.78 | SLC6A2 (0.46) | SLC6A4OPRD1SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1172872 | 0.78 | OPRM1 (0.58) | OPRD1SLC6A3KCNH2OPRM1SIGMAR1 | |
| SCHEMBL924025 | 0.77 | TACR1 (0.49) | TACR1SLC6A4OPRD1SLC6A2SLC6A3 | |
| SCHEMBL1172750 | 0.76 | OPRM1 (0.56) | OPRD1SLC6A3KCNH2OPRM1SIGMAR1 | |
| SCHEMBL5143490 | 0.76 | SLC6A4 (0.46) | TACR1SLC6A4OPRD1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009449-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-01-13 | — | — | US | claimed |
| US-20110046180-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20110046180-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20110046180-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20110009449-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-01-13 | — | — | US | disclosed |
| US-20110009449-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-01-13 | — | — | US | disclosed |
| US-20110009449-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-01-13 | — | — | US | disclosed |
| EP-2234616-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077585-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077585-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077584-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046180-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | OPRL1, OPRD1, OPRK1 | TACR1 50/4885SLC6A4 853/4885OPRD1 2/4885 |
| US-20110009449-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, OPRL1 | TACR1 139/4885SLC6A4 4/4885OPRD1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.